Recovery outcomes for esophageal cancer after complete response to pre-surgery treatment
Part of Cancer, Digestive system clinical trials.
This study looks at patients with esophageal cancer who had a complete response to treatment given before surgery, meaning no cancer was found when the tumor was removed. It aims to understand their long-term outcomes and help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had chemotherapy, radiation, or both before surgery for esophageal cancer between 2018 and 2023.
- Your cancer was a type called squamous cell carcinoma, located in the chest (thoracic area).
- Your cancer stage before treatment was cT1N+M0 or cT2-4aN0-3M0, meaning it had not spread to distant organs.
- After surgery, your pathology report showed no cancer cells (complete pathological response, ypT0N0M0).
- You had no distant metastases before surgery, and the tumor did not invade nearby organs like the pancreas, spleen, trachea, aorta, or lungs.
- You have no history of other cancers, and your treatment and medical records are complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a way to predict whether immunotherapy (a treatment that helps your immune system fight cancer) will completely eliminate esophageal cancer before surgery. By examining lymph nodes, they hope to tailor treatment more personally.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study looks back at patients who received immunotherapy and chemotherapy before surgery for esophageal cancer, to see how often the cancer comes back after surgery. It may help doctors understand which patients benefit the most from this treatment approach.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.